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Soft tissue injuries and tendinopathies account for large 
numbers of chronic musculoskeletal disorders. 
Extracorporeal shockwave therapy (ESWT) is popular, 
and effective in the management of chronic tendon 
conditions in the elbow, shoulder, and pain at and 
around the heel. 
 
Methods/Design 
Ethical approval was granted from the South East 
London Research Ethics Committee to implement a 
database for the Assessment of Effectiveness of 
Extracorporeal Shock Wave Therapy for Soft Tissue 
Injuries (ASSERT) to prospectively collect information 
on the effectiveness of ESWT across the UK. All 
participants will give informed consent. All clinicians 
follow a standardised method of administration of the 
ESWT. The primary outcome measures are validated 
outcome measures specific to the condition being 
treated. A Visual Analogue Score for pain and the 
EuroQol will be completed alongside the condition 
specific outcome tool at baseline, 3, 6, 12 and 24 months 
post treatment.  
 
Discussion 
The development of the ASSERT database will enable 
the evaluation of the effectiveness of ESWT for patients 
suffering from chronic conditions (plantar fasciopathy, 
tennis elbow, Achilles tendinopathy, greater trochanter 
pain syndrome and patellar tendinopathy). The results 
will aid the clinicians in the decision making process 
when managing these patients. 
 
Key Words 
Chronic soft tissue injuries, extracorporeal shockwave 
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Background 
Soft tissue injuries and tendinopathies are common, and 
account for a large number of chronic musculoskeletal 
disorders Tendinopathy is a common debilitating 
condition
1 
which presents a challenge to clinicians and 
therapists
2
. The most common tendinopathies involve 
the Achilles tendon, medial and lateral epicondyles, 
patellar tendon and the rotator cuff, and patients may 
endure pain and disability for years
3,4
. 
Shock wave therapy (SWT) has been successfully 
employed since the late 1980s for the management of 
various musculoskeletal, disorders including plantar 
fasciopathy, Achilles tendinopathy, shoulder calcific 
tendinitis, and lateral epicondylitis
5
. Some trials have 
evidenced negative results 
6,7,8,9
, but there are now many 
well performed randomized, double-blind, clinical trials 
which support the use of SWT
10,11,12,13,14,15,16,17,18,19,20
. 
Extracorporeal shockwave therapy (ESWT) is effective 
in the management of a number of chronic tendon 
conditions in the elbow, shoulder, and pain at and 
around the heel. When other forms of conservative 
therapy have not been effective in relieving pain and 






Despite the growing numbers of published studies on 
ESWT supporting its use, there is still uncertainty 
around the use of ESWT and its clinical effectiveness 
remains controversial. Further research needs to be 
undertaken, utilising a homogenous intervention; 
identical outcome assessment; comparable participants 
and comparable follow-up evaluation for all the 
conditions for which ESWT is used as a treatment 
modality
21
. The National Institute for Health and 
Clinical Excellence (NICE) has published guidance on 
the use of ESWT in calcific tendinopathy of the 
shoulder
22
, recommending that the results of the 
procedure are monitored, and clinicians undertaking the 





 and Achilles 
tendinopathy 
25
, NICE recognise that the procedure is 
efficacious in selected patients, and therefore has the 
potential for a high clinical impact. This makes 
provision of robust data particularly important; NICE 
requests that clinicians undertaking the procedure make 
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special arrangements for audit. For greater trochanter 
pain syndrome 
26
, NICE identified that 70% of patients 
would recommend this procedure to others, and requires 
that clinicians undertaking the procedure make special 
arrangements for audit. For patellar tendinopathy, there 
is no NICE guidance, but ESWT in patellar 





The primary aim of the Assessment of Effectiveness of 
Extracorporeal Shock Wave Therapy (ESWT) for Soft 
Tissue Injuries (ASSERT) database is to determine the 
effectiveness of ESWT in patients suffering from 
refractory plantar fasciopathy, tennis elbow, Achilles 
tendonopathy, greater trochanter pain syndrome, patellar 
tendinopathy in both the short and long term. 
 
Methods/Design 
An online database (ASSERT) has been developed and 
implemented to collect information on the effectiveness 
of ESWT across the UK. A standard ESWT machine 
(Swiss Dolorclast) and a standardised treatment 
protocol, together with standardised baseline 
measurements and outcome measures and time points in 
centres across the UK have been adopted to aid validity.  
 
Recruitment 
Participants will be recruited from (both the NHS and 
private sectors) centres in the UK where have the Swiss 
Dolorclast Shockwave Machine (EMS Ch. de la 
Vuarpillière 31, 1260 Nyon 
Switzerland) is used.  Clinicians will recruit participants 
presenting with one of the refractory conditions as 
indicated above and for whom ESWT has been indicated 
as a treatment choice.  
 
Participants 
Participants will be included if they are over the age of 
16 and have: 
 A diagnosis of plantar fasciopathy; tennis 
elbow; Achilles tendinopathy; greater trochanter pain 
syndrome; or patellar tendinopathy which has been 
confirmed by a recruiting clinician and validated by 
MRI scan or ultrasound scan with power Doppler 
 Underwent a course of conservative therapy 
which has not been effective in relieving pain and other 
symptoms  
 Been recommended to receive ESWT at one of 
the identified centres 
 No inflammatory arthropathies 
 Demonstrated the ability to give informed 
consent. 
 
Use of ESWT Machine 
Standardisation of the machine and the process of 
administration of ESWT has been agreed to ensure 
consistency, reproducibility and generalisability of the 
results. All clinicians using the Swiss Dolorclast 
machine will receive training and certification to ensure 
adherence to the protocol. All clinicians follow the 
Gerdesmeyer method. This includes delivering an initial 
500 sensitising impulses at a low air pressure (1.5 bar of 
air pressure) which reduces the pain the patient 
experiences during the treatment. Based on patient 
feedback, the clinician increases the air pressure to 2.5 
bar or above. Overall, irrespective of the area being 
treated, the total dose of impulses remains constant at 
2500 per session, with one session a week for 3 
consecutive weeks, with a maximum gap between 
treatments of 2 weeks. 
 
Database 
The ASSERT database is a web based system 
(www.assert.org.uk) from which the clinician receives a 
study number for each participant. Only unidentifiable 
information with the patients study number is entered 
into the database. Sensitive data is held on secure 
servers. 
 
Following informed consent, the clinician records the 
following information: 
 
 Diagnosis as diagnosed by an MRI scan or 
ultrasound scan with power or colour Doppler (relevant 
images to be imported onto a JPeg for review)  
 Area to be treated/condition presenting with 
 Date of presentation of symptoms 
 Date of treatment of ESWT 
 Code for clinicians centre 
 Centre where treatment is administered 
 Record any other forms of treatment have been 
administered prior to consultation and what treatment 
 Side the treatment is being administered 
(Right/Left/Bilateral) 
 Dates ESWT administered 
 Baseline score recorded: EuroQol (EQ-5D)28 
and VAS for pain and validated outcome measures 
according to condition (listed in the outcome measures 
section)  
 Follow-up scores at 3, 6, 12 and 24 months post 
treatment using validated scoring systems according to 
the condition 
 Visual Analogue Scale (VAS) for pain 
 Satisfaction (rated poor, satisfactory, good or 
excellent) 
 Time to effective treatment 
 Recurrence of condition 
 Complications 
 Adverse events 
 
Arrangements for monitoring the database’s systems 
and procedures 
A data monitoring committee has been formed, 
consisting of members of the study team, including a lay 
member and an independent chair, who will meet on a 
regular basis to review the progress of ASSERT and 
database management. 
 
Data collection pilot 
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Prior to commencement of the data collection, a pilot 
test with three nominated clinicians and two lay 
members tested the feasibility of using the database to 
collate information on patients having ESWT. All 
recruiting clinicians have to complete the mandatory 
training to ensure they are both competent to administer 
the ESWT with the Swiss Dolorclast Machine and they 
are fully conversant with GCP guidelines and competent 




Baseline assessments will be undertaken by the treating 
clinician following informed consent 
 
Follow-up Assessments 
Outcomes will be assessed at baseline, 3,6,12 and 24 
months post treatment. The clinician will undertake the 
3 months assessment and the co-ordinators of ASSERT 




For all conditions the VAS and the EuroQol
28
 will be 
completed alongside the condition specific outcome 
tool. VAS is a horizontal line, 100 mm in length asking 
the patient “How severe is your pain today?” and to 
indicate on the line how bad their pain is on that day, 
with one end being “no pain” and the other being “very 
severe pain”. The EQ-5D
28
 is a standardised measure of 
health status developed by the EuroQol Group to 
provide a simple, generic measure of health for clinical 
and economic appraisal. It is a simple questionnaire 
designed for completion by the person being treated. 
The primary outcome measures are specific to the 
condition being treated and are listed below: 
Outcome Measures 
Calcific tendinopathy of the shoulder  
The Upper Extremity Function Scale
29 
is a self-
administered questionnaire which can be used to 
measure the impact of upper extremity disorders on a 
person's ability to perform physical tasks. It can be used 
to monitor the patient over time both to detect worsening 
of the condition and to assess response to a therapeutic 
intervention. 
Plantar Fasciopathy 
The Foot Function Score
30 
is a specific foot function 
score which provides information as to how foot pain 
has affected a persons ability to manage in every day 
life.  
Tennis Elbow 
The Patient Rated Tennis Elbow Evaluation (PRTEE)
31
 
is a 15-item questionnaire designed to measure forearm 
pain and disability in patients with lateral epicondylitis 
(also known as “tennis elbow”). The PRTEE allows 
patients to rate their levels of tennis elbow pain and 
disability. 
Achilles Tendinopathy  
The VISA-A
32
 is an index of severity of Achilles 
tendinopathy.  The continuous numerical result of the 
VISA-A questionnaire has the potential to provide utility 
in both the clinical setting and research. The VISA-A 
score can identify patients who need more
 
aggressive 
management, and can be used to monitor their progress. 
Greater Trochanter Pain Syndrome 
The Lower Extremity Functional Score
33
. The Lower 
Extremity Functional Scale (LEFS) can be used to 
evaluate the functional impairment of a patient with a 
disorder of one or both lower extremities. It can be used 
to monitor the patient over time and to evaluate the 
effectiveness of an intervention. 
Patellar tendinopathy  
The VISA-P Outcome Score
34
 is a questionnaire 
developed for patients with patellar tendinopathy. 
Patients assess severity of symptoms, function and 
ability to participate in sport. 
 
The two-year follow-up period will ensure a long 
enough follow-up to time to assess the treatment effects, 









Descriptive and comparison statistics will be performed 
on all variables using the SPSS-19 statistics package. 
 
Ethics 
ASSERT will take place in centres across the UK both 
in the NHS and the private sectors following the 
principles of the Helsinki declaration and following 
Good Clinical practice Guidelines (GCP). Ethical 
approval for ASSERT was granted from the South East 
London NRES committee (REC Ref: 11/LO/0253). 
Participants will receive information about ASSERT 
before providing their written consent. All data collected 
will be confidential. 
 
Discussion 
At present, ESWT is only used in few centres, and the 
effectiveness of the treatment being monitored in a non 
consistent manner. There is no UK database which 
monitors the efficacy of the treatment in the formal 
manner as recommended by NICE. The development of 
this database will allow documentation of the 
recruitment and outcome of ESWT in a scientific 
fashion.  Collecting information in a pragmatic and yet 
systematic way via the ASSERT database will ensure 
the evaluation of the effectiveness of this already 
established treatment both in the short and long term and 
will facilitate its use in the wider community.  
 
 
List of Abbreviations 
ASSERT Assessment of the Effectiveness of 
Extracorporeal Shock Wave Therapy for Soft Tissue 
Injuries 
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ESWT Extracorporeal Shock Wave Therapy 
NICE National Institute of Clinical Excellence 
VAS Visual Analogue Score 
EQ-5D EuroQol Quality of Life Outcome Measure 
PRTEE Patient Related Tennis Elbow Evaluation 
VISA-A Victorian Institute of Sport Assessment-
Achilles Questionnaire 








The ASSERT Database has been developed and 
established through funds provided by Industry 
(Spectrum Technology UK) and EPSRC grants. The 
funds enable GM and SH to develop, establish and 
coordinate ASSERT.  
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